Actelion top-40 investor calls J&J buyout "very attractive"
ZURICH, Jan 26 (Reuters) - Johnson & Johnson's $30 billion offer to buy Swiss biotech Actelion including a plan to spin out a separate research company is "very attractive", one of Actelion's 40... [Source]
Publication Date:Origin: reuters.com
Category: mergersNews
Topics: Actelion, Actelion's, "very attractive", company, research, separate, a plan, including, biotech, Swiss, offer, $30 billion, Johnson's, Johnson, (Reuters), ZURICH, attractive", "very, buyout, calls, investor, top-40